New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
07:14 EDTEXASExact Sciences announces FDA approved Cologuard
Exact Sciences announced that the FDA has approved Cologuard, the company's noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers.
News For EXAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
10:52 EDTEXASLeerink's life science tools analyst holds an analyst/industry conference call
Subscribe for More Information
08:05 EDTEXASExact Sciences says Tufts Health Plan to cover Cologuard
Subscribe for More Information
March 26, 2015
10:04 EDTEXASOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:23 EDTEXASOn The Fly: Pre-market Movers
Subscribe for More Information
06:07 EDTEXASExact Sciences downgraded to Neutral from Buy at Goldman
Goldman downgraded Exact Sciences to Neutral to reflect lower revenue estimates for Cologuard adoption. Price target lowered to $24 from $29.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use